Literature DB >> 30500399

miR-146a mediates thymosin β4 induced neurovascular remodeling of diabetic peripheral neuropathy in type-II diabetic mice.

Lei Wang1, Michael Chopp2, XueRong Lu3, Alexandra Szalad3, LongFei Jia3, Xian Shuang Liu3, Kuan-Han Wu4, Mei Lu4, Zheng Gang Zhang3.   

Abstract

Diabetes induces neurovascular dysfunction leading to peripheral neuropathy. MicroRNAs (miRNAs) affect many biological processes and the development of diabetic peripheral neuropathy. In the present study, we investigated whether thymosin-β4 (Tβ4) ameliorates diabetic peripheral neuropathy and whether miR-146a mediates the effect of Tβ4 on improved neurovascular function. Male Type II diabetic BKS. Cg-m+/+Leprdb/J (db/db) mice at age 20 weeks were treated with Tβ4 for 8 consecutive weeks, and db/db mice treated with saline were used as a control group. Compared to non-diabetic mice, diabetic mice exhibited substantially reduced miR-146a expression, and increased IL-1R-associated kinase-1 (IRAK1), tumor necrosis factor (TNFR)-associated factor 6 (TRAF6) levels and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) activity in sciatic nerve tissues. Treatment of diabetic mice with Tβ4 significantly elevated miR-146a levels and overcame the effect of diabetes on these proteins. Tβ4 treatment substantially improved motor and sensory conduction velocity of the sciatic nerve, which was associated with improvements in sensory function. Tβ4 treatment significantly increased intraepidermal nerve fiber density and augmented local blood flow and the density of fluorescein isothiocyanate (FITC)-dextran perfused vessels in the sciatic nerve tissue. In vitro, treatment of dorsal root ganglion (DRG) neurons and mouse dermal endothelial cells (MDEs) with Tβ4 significantly increased axonal outgrowth and capillary-like tube formation, whereas blocking miR-146a attenuated Tβ4-induced axonal outgrowth and capillary tube formation, respectively. Our data indicate that miR-146a may mediate Tβ4-induced neurovascular remodeling in diabetic mice, by suppressing pro-inflammatory signals.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diabetes; Mice; Peripheral neuropathy; Thymosin β4; miR-146a

Mesh:

Substances:

Year:  2018        PMID: 30500399      PMCID: PMC6372311          DOI: 10.1016/j.brainres.2018.11.039

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  51 in total

1.  Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke.

Authors:  D C Morris; M Chopp; L Zhang; M Lu; Z G Zhang
Journal:  Neuroscience       Date:  2010-08-25       Impact factor: 3.590

2.  Development of diabetic neuropathy in the C57BL/Ks (db/db) mouse and its treatment with gangliosides.

Authors:  F Norido; R Canella; R Zanoni; A Gorio
Journal:  Exp Neurol       Date:  1984-02       Impact factor: 5.330

3.  Thymosin β4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases.

Authors:  Michael Chopp; Zheng Gang Zhang
Journal:  Expert Opin Biol Ther       Date:  2015-01-22       Impact factor: 4.388

4.  Inflammatory mediators in diabetic and non-diabetic lumbosacral radiculoplexus neuropathy.

Authors:  Nobutoshi Kawamura; P James B Dyck; Ann M Schmeichel; JaNean K Engelstad; Phillip A Low; Peter J Dyck
Journal:  Acta Neuropathol       Date:  2007-12-05       Impact factor: 17.088

5.  Pyruvate Dehydrogenase Kinase-mediated Glycolytic Metabolic Shift in the Dorsal Root Ganglion Drives Painful Diabetic Neuropathy.

Authors:  Md Habibur Rahman; Mithilesh Kumar Jha; Jong-Heon Kim; Youngpyo Nam; Maan Gee Lee; Younghoon Go; Robert A Harris; Dong Ho Park; Hyun Kook; In-Kyu Lee; Kyoungho Suk
Journal:  J Biol Chem       Date:  2016-01-14       Impact factor: 5.157

6.  Chemokine (C-C motif) ligand 2 (CCL2) in sera of patients with type 1 diabetes and diabetic complications.

Authors:  Ruili Guan; Sharad Purohit; Hongjie Wang; Bruce Bode; John Chip Reed; R Dennis Steed; Stephen W Anderson; Leigh Steed; Diane Hopkins; Chun Xia; Jin-Xiong She
Journal:  PLoS One       Date:  2011-04-12       Impact factor: 3.240

7.  Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers.

Authors:  Amandine I Garcia; Monique Buisson; Pascale Bertrand; Ruth Rimokh; Etienne Rouleau; Bernard S Lopez; Rosette Lidereau; Ivan Mikaélian; Sylvie Mazoyer
Journal:  EMBO Mol Med       Date:  2011-04-05       Impact factor: 12.137

8.  Thymosin β4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing.

Authors:  Mark A Evans; Nicola Smart; Karina N Dubé; Sveva Bollini; James E Clark; Hayley G Evans; Leonie S Taams; Rebecca Richardson; Mathieu Lévesque; Paul Martin; Kevin Mills; Johannes Riegler; Anthony N Price; Mark F Lythgoe; Paul R Riley
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  Vascular Cell Adhesion Molecule 1, Intercellular Adhesion Molecule 1, and Cluster of Differentiation 146 Levels in Patients with Type 2 Diabetes with Complications.

Authors:  F Sinem Hocaoglu-Emre; Devrim Saribal; Guven Yenmis; Guvenc Guvenen
Journal:  Endocrinol Metab (Seoul)       Date:  2017-03

10.  The association of vitamin D with inflammatory cytokines in diabetic peripheral neuropathy.

Authors:  Bulent Bilir; Feti Tulubas; Betul Ekiz Bilir; Neslihan Soysal Atile; Sonat Pinar Kara; Tulay Yildirim; Seyit Ali Gumustas; Birol Topcu; Ozlem Kaymaz; Murat Aydin
Journal:  J Phys Ther Sci       Date:  2016-07-29
View more
  2 in total

Review 1.  Exercise, redox homeostasis and the epigenetic landscape.

Authors:  Ivan Dimauro; Maria Paola Paronetto; Daniela Caporossi
Journal:  Redox Biol       Date:  2020-02-26       Impact factor: 11.799

Review 2.  Genetic and Epigenomic Modifiers of Diabetic Neuropathy.

Authors:  Milena Jankovic; Ivana Novakovic; Dejan Nikolic; Jasmina Mitrovic Maksic; Slavko Brankovic; Ivana Petronic; Dragana Cirovic; Sinisa Ducic; Mirko Grajic; Dragana Bogicevic
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.